# C_2016370EN.01001701.xml

| 8.10.2016 | EN | Official Journal of the European Union | C 370/17 |
| --- | --- | --- | --- |

8.10.2016

EN

Official Journal of the European Union

C 370/17

---

Prior notification of a concentration

(Case M.8060 — Abbott Laboratories/St. Jude Medical)

(Text with EEA relevance)

(2016/C 370/06)

| 1. | On 3 October 2016, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Abbott Laboratories (USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of St. Jude Medical, Inc. (USA) by way of purchase of shares. |
| --- | --- |

1.

On 3 October 2016, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Abbott Laboratories (USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of St. Jude Medical, Inc. (USA) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   Abbott Laboratories: research, development, manufacture and supply of a diversified range of health care products, such as nutritional products, medical devices, diagnostic products and pharmaceutical products,
  —   St. Jude Medical, Inc.: research, development, manufacture and supply of medical devices, such as cardiac rhythm, heart failure, cardiovascular, atrial fibrillation and neuromodulation products. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   Abbott Laboratories: research, development, manufacture and supply of a diversified range of health care products, such as nutritional products, medical devices, diagnostic products and pharmaceutical products,

Abbott Laboratories

—   St. Jude Medical, Inc.: research, development, manufacture and supply of medical devices, such as cardiac rhythm, heart failure, cardiovascular, atrial fibrillation and neuromodulation products.

St. Jude Medical, Inc.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8060 — Abbott Laboratories/St. Jude Medical, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8060 — Abbott Laboratories/St. Jude Medical, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---